Publications

  1. Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins. J Clin Invest. 2024 Jun 13; 134(15). View Abstract

  2. Hematopoietic stem cell division is governed by distinct RUNX1 binding partners. bioRxiv. 2024 Jun 08. View Abstract

  3. Welcoming the Era of Gene Editing in Medicine. N Engl J Med. 2024 May 09; 390(18):1642-1645. View Abstract

  4. Dynamic nucleolar phase separation influenced by non-canonical function of LIN28A instructs pluripotent stem cell fate decisions. Nat Commun. 2024 Feb 10; 15(1):1256. View Abstract

  5. Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology. NAM Perspect. 2023; 2023. View Abstract

  6. Development of functional resident macrophages in human pluripotent stem cell-derived colonic organoids and human fetal colon. Cell Stem Cell. 2023 11 02; 30(11):1434-1451.e9. View Abstract

  7. Extracellular vesicles improve GABAergic transmission in Huntington's disease iPSC-derived neurons. Theranostics. 2023; 13(11):3707-3724. View Abstract

  8. Raman microspectroscopy reveals unsaturation heterogeneity at the lipid droplet level and validates an in vitro model of bone marrow adipocyte subtypes. Front Endocrinol (Lausanne). 2022; 13:1001210. View Abstract

  9. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell. 2022 08 04; 29(8):1181-1196.e6. View Abstract

  10. Lifelong multilineage contribution by embryonic-born blood progenitors. Nature. 2022 06; 606(7915):747-753. View Abstract

  11. Anniversary reflections: ISSCR presidents on 20 years of progress. Cell Stem Cell. 2022 06 02; 29(6):876-878. View Abstract

  12. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell Rep. 2022 04 26; 39(4):110752. View Abstract

  13. CellComm infers cellular crosstalk that drives haematopoietic stem and progenitor cell development. Nat Cell Biol. 2022 04; 24(4):579-589. View Abstract

  14. Developmental maturation of the hematopoietic system controlled by a Lin28b-let-7-Cbx2 axis. Cell Rep. 2022 04 05; 39(1):110587. View Abstract

  15. Dipping a toe in the fountain of youth. Nat Aging. 2022 03; 2(3):192-194. View Abstract

  16. Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Sci Immunol. 2022 01 21; 7(67):eabk3070. View Abstract

  17. LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy. J Clin Invest. 2021 11 15; 131(22). View Abstract

  18. rRNA biogenesis regulates mouse 2C-like state by 3D structure reorganization of peri-nucleolar heterochromatin. Nat Commun. 2021 11 09; 12(1):6365. View Abstract

  19. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738. View Abstract

  20. LIN28 coordinately promotes nucleolar/ribosomal functions and represses the 2C-like transcriptional program in pluripotent stem cells. Protein Cell. 2022 07; 13(7):490-512. View Abstract

  21. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. View Abstract

  22. Lin28 paralogs regulate lung branching morphogenesis. Cell Rep. 2021 07 20; 36(3):109408. View Abstract

  23. Sequential regulation of hemogenic fate and hematopoietic stem and progenitor cell formation from arterial endothelium by Ezh1/2. Stem Cell Reports. 2021 07 13; 16(7):1718-1734. View Abstract

  24. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. Stem Cell Reports. 2021 06 08; 16(6):1398-1408. View Abstract

  25. Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. Sci Transl Med. 2020 10 21; 12(566). View Abstract

  26. An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation. Blood Adv. 2020 10 13; 4(19):4679-4692. View Abstract

  27. Mitochondrial and Redox Modifications in Huntington Disease Induced Pluripotent Stem Cells Rescued by CRISPR/Cas9 CAGs Targeting. Front Cell Dev Biol. 2020; 8:576592. View Abstract

  28. Diversification of reprogramming trajectories revealed by parallel single-cell transcriptome and chromatin accessibility sequencing. Sci Adv. 2020 09; 6(37). View Abstract

  29. Metabolic Regulation of Inflammasome Activity Controls Embryonic Hematopoietic Stem and Progenitor Cell Production. Dev Cell. 2020 10 26; 55(2):133-149.e6. View Abstract

  30. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. Nat Commun. 2020 07 03; 11(1):3303. View Abstract

  31. LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors. Proc Natl Acad Sci U S A. 2020 07 14; 117(28):16516-16526. View Abstract

  32. COVID Highlights Another Crisis: Lack of Black Physicians and Scientists. Med. 2021 01 15; 2(1):2-3. View Abstract

  33. Oral health care in the 21st century: It is time for the integration of dental and medical education. J Dent Educ. 2020 Sep; 84(9):999-1002. View Abstract

  34. Transcriptome Dynamics of Hematopoietic Stem Cell Formation Revealed Using a Combinatorial Runx1 and Ly6a Reporter System. Stem Cell Reports. 2020 05 12; 14(5):956-971. View Abstract

  35. The Toughest Triage - Allocating Ventilators in a Pandemic. N Engl J Med. 2020 May 21; 382(21):1973-1975. View Abstract

  36. Author Correction: Lin28 and let-7 regulate the timing of cessation of murine nephrogenesis. Nat Commun. 2020 Mar 09; 11(1):1327. View Abstract

  37. A nanobody targeting the LIN28:let-7 interaction fragment of TUT4 blocks uridylation of let-7. Proc Natl Acad Sci U S A. 2020 03 03; 117(9):4653-4663. View Abstract

  38. YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biomechanical Forces of Blood Flow. Dev Cell. 2020 02 24; 52(4):446-460.e5. View Abstract

  39. Introduction to the Special Issue on CRISPR. Perspect Biol Med. 2020; 63(1):1-13. View Abstract

  40. Author Correction: Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature. 2019 Sep; 573(7772):E1. View Abstract

  41. Author Correction: A systems biology pipeline identifies regulatory networks for stem cell engineering. Nat Biotechnol. 2019 Aug; 37(8):962. View Abstract

  42. A systems biology pipeline identifies regulatory networks for stem cell engineering. Nat Biotechnol. 2019 07; 37(7):810-818. View Abstract

  43. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019 07; 20(7):377-388. View Abstract

  44. Stem Cells in the Treatment of Disease. N Engl J Med. 2019 05 02; 380(18):1748-1760. View Abstract

  45. Retraction Note: NF-?B activation impairs somatic cell reprogramming in ageing. Nat Cell Biol. 2019 Mar; 21(3):410. View Abstract

  46. The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia. J Exp Med. 2019 03 04; 216(3):527-538. View Abstract

  47. The Lin28/let-7 Pathway Regulates the Mammalian Caudal Body Axis Elongation Program. Dev Cell. 2019 02 11; 48(3):396-405.e3. View Abstract

  48. After the Storm - A Responsible Path for Genome Editing. N Engl J Med. 2019 Mar 07; 380(10):897-899. View Abstract

  49. Lin28 and let-7 regulate the timing of cessation of murine nephrogenesis. Nat Commun. 2019 01 11; 10(1):168. View Abstract

  50. Lin28b regulates age-dependent differences in murine platelet function. Blood Adv. 2019 01 08; 3(1):72-82. View Abstract

  51. Building Capacity for a Global Genome Editing Observatory: Institutional Design. Trends Biotechnol. 2018 08; 36(8):741-743. View Abstract

  52. Small-Molecule Inhibitors Disrupt let-7 Oligouridylation and Release the Selective Blockade of let-7 Processing by LIN28. Cell Rep. 2018 06 05; 23(10):3091-3101. View Abstract

  53. Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges. Trends Biotechnol. 2018 07; 36(7):639-641. View Abstract

  54. A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development. Cell Stem Cell. 2018 04 05; 22(4):575-588.e7. View Abstract

  55. Reconstruction of complex single-cell trajectories using CellRouter. Nat Commun. 2018 03 01; 9(1):892. View Abstract

  56. Regulation of embryonic haematopoietic multipotency by EZH1. Nature. 2018 01 25; 553(7689):506-510. View Abstract

  57. Comprehensive Mapping of Pluripotent Stem Cell Metabolism Using Dynamic Genome-Scale Network Modeling. Cell Rep. 2017 Dec 05; 21(10):2965-2977. View Abstract

  58. Is There Merit in Merit Aid? N Engl J Med. 2017 Dec 21; 377(25):2415-2417. View Abstract

  59. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration. Mol Ther. 2017 Sep 06; 25(9):1999-2013. View Abstract

  60. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature. 2017 05 25; 545(7655):432-438. View Abstract

  61. Reassembling embryos in vitro from component stem cells. Cell Res. 2017 Aug; 27(8):961-962. View Abstract

  62. Autophagy: It's in Your Blood. Dev Cell. 2017 03 27; 40(6):518-520. View Abstract

  63. Polar Extremes in the Clinical Use of Stem Cells. N Engl J Med. 2017 03 16; 376(11):1075-1077. View Abstract

  64. Signaling through RNA-binding proteins as a cell fate regulatory mechanism. Cell Cycle. 2017 04 18; 16(8):723-724. View Abstract

  65. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci Transl Med. 2017 02 08; 9(376). View Abstract

  66. Disruptive reproductive technologies. Sci Transl Med. 2017 01 11; 9(372). View Abstract

  67. Engineered Murine HSCs Reconstitute Multi-lineage Hematopoiesis and Adaptive Immunity. Cell Rep. 2016 12 20; 17(12):3178-3192. View Abstract

  68. LIN28 phosphorylation by MAPK/ERK couples signalling to the post-transcriptional control of pluripotency. Nat Cell Biol. 2017 Jan; 19(1):60-67. View Abstract

  69. Stem cells: Valine starvation leads to a hungry niche. Nature. 2017 01 12; 541(7636):166-167. View Abstract

  70. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017 04; 31(4):853-860. View Abstract

  71. TGF-ß inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors. Blood. 2016 12 08; 128(23):2637-2641. View Abstract

  72. Progress towards generation of human haematopoietic stem cells. Nat Cell Biol. 2016 Nov; 18(11):1111-1117. View Abstract

  73. Developmental Vitamin D Availability Impacts Hematopoietic Stem Cell Production. Cell Rep. 2016 10 04; 17(2):458-468. View Abstract

  74. Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. J Exp Med. 2016 07 25; 213(8):1497-512. View Abstract

  75. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature. 2016 07 14; 535(7611):246-51. View Abstract

  76. LIN28 Regulates Stem Cell Metabolism and Conversion to Primed Pluripotency. Cell Stem Cell. 2016 07 07; 19(1):66-80. View Abstract

  77. RNAi Reveals Phase-Specific Global Regulators of Human Somatic Cell Reprogramming. Cell Rep. 2016 06 21; 15(12):2597-607. View Abstract

  78. Engineering Hematopoietic Stem Cells: Lessons from Development. Cell Stem Cell. 2016 06 02; 18(6):707-720. View Abstract

  79. Policy: Global standards for stem-cell research. Nature. 2016 05 19; 533(7603):311-3. View Abstract

  80. New ISSCR guidelines: clinical translation of stem cell research. Lancet. 2016 May 14; 387(10032):1979-81. View Abstract

  81. SCIENTIFIC COMMUNITY. Confronting stem cell hype. Science. 2016 May 13; 352(6287):776-7. View Abstract

  82. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. Stem Cell Reports. 2016 06 14; 6(6):787-797. View Abstract

  83. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016 05; 101(5):541-58. View Abstract

  84. Interferon-a signaling promotes embryonic HSC maturation. Blood. 2016 07 14; 128(2):204-16. View Abstract

  85. Sex-specific regulation of weight and puberty by the Lin28/let-7 axis. J Endocrinol. 2016 Mar; 228(3):179-91. View Abstract

  86. Corrigendum: Failure to replicate the STAP cell phenomenon. Nature. 2016 Mar 17; 531(7594):400. View Abstract

  87. Corrigendum: Hallmarks of pluripotency. Nature. 2016 Mar 17; 531(7594):400. View Abstract

  88. Stem cells and the evolving notion of cellular identity. Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19; 370(1680):20140376. View Abstract

  89. Precise let-7 expression levels balance organ regeneration against tumor suppression. Elife. 2015 Oct 07; 4:e09431. View Abstract

  90. Failure to replicate the STAP cell phenomenon. Nature. 2015 Sep 24; 525(7570):E6-9. View Abstract

  91. Hallmarks of pluripotency. Nature. 2015 Sep 24; 525(7570):469-78. View Abstract

  92. Hematopoietic stem cells develop in the absence of endothelial cadherin 5 expression. Blood. 2015 Dec 24; 126(26):2811-20. View Abstract

  93. Systematic identification of factors for provirus silencing in embryonic stem cells. Cell. 2015 Sep 24; 163(1):230-45. View Abstract

  94. PRC2 Is Required to Maintain Expression of the Maternal Gtl2-Rian-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells. Cell Rep. 2015 Sep 01; 12(9):1456-70. View Abstract

  95. NF-?B activation impairs somatic cell reprogramming in ageing. Nat Cell Biol. 2015 Aug; 17(8):1004-13. View Abstract

  96. Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature. 2015 Jul 23; 523(7561):468-71. View Abstract

  97. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. View Abstract

  98. Integrative Analyses of Human Reprogramming Reveal Dynamic Nature of Induced Pluripotency. Cell. 2015 Jul 16; 162(2):412-424. View Abstract

  99. Two new routes to make blood: Hematopoietic specification from pluripotent cell lines versus reprogramming of somatic cells. Exp Hematol. 2015 Sep; 43(9):756-9. View Abstract

    100. Transplantation of Macaca cynomolgus iPS-derived hematopoietic cells in NSG immunodeficient mice. Haematologica. 2015 Oct; 100(10):e428-31. View Abstract

  100. LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes Dev. 2015 May 15; 29(10):1074-86. View Abstract

  101. Correction: Transplantation of Adult Mouse iPS Cell-Derived Photoreceptor Precursors Restores Retinal Structure and Function in Degenerative Mice. PLoS One. 2015; 10(5):e0125947. View Abstract

  102. Biomechanical forces promote blood development through prostaglandin E2 and the cAMP-PKA signaling axis. J Exp Med. 2015 May 04; 212(5):665-80. View Abstract

  103. Adenosine signaling promotes hematopoietic stem and progenitor cell emergence. J Exp Med. 2015 May 04; 212(5):649-63. View Abstract

  104. Flow-induced protein kinase A-CREB pathway acts via BMP signaling to promote HSC emergence. J Exp Med. 2015 May 04; 212(5):633-48. View Abstract

  105. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science. 2015 Apr 03; 348(6230):36-8. View Abstract

  106. De novo generation of HSCs from somatic and pluripotent stem cell sources. Blood. 2015 Apr 23; 125(17):2641-8. View Abstract

  107. Metabolic switches linked to pluripotency and embryonic stem cell differentiation. Cell Metab. 2015 Mar 03; 21(3):349-50. View Abstract

  108. The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy. Leukemia. 2015 Jun; 29(6):1320-30. View Abstract

  109. Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium. Blood. 2015 Feb 26; 125(9):1418-26. View Abstract

  110. Dissecting reprogramming, differentiation and conversion with network biology. Leuk Suppl. 2014 Dec; 3(Suppl 1):S3-4. View Abstract

  111. Deconstructing transcriptional heterogeneity in pluripotent stem cells. Nature. 2014 Dec 04; 516(7529):56-61. View Abstract

  112. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015 Jan; 33(1):58-63. View Abstract

  113. A nontranscriptional role for Oct4 in the regulation of mitotic entry. Proc Natl Acad Sci U S A. 2014 Nov 04; 111(44):15768-73. View Abstract

  114. Deriving blood stem cells from pluripotent stem cells for research and therapy. Best Pract Res Clin Haematol. 2014 Sep-Dec; 27(3-4):293-7. View Abstract

  115. The epithelial-mesenchymal transition factor SNAIL paradoxically enhances reprogramming. Stem Cell Reports. 2014 Nov 11; 3(5):691-8. View Abstract

  116. Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science. 2014 Aug 22; 345(6199):1247391. View Abstract

  117. CellNet: network biology applied to stem cell engineering. Cell. 2014 Aug 14; 158(4):903-915. View Abstract

  118. Dissecting engineered cell types and enhancing cell fate conversion via CellNet. Cell. 2014 Aug 14; 158(4):889-902. View Abstract

  119. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell. 2014 Aug 11; 26(2):248-61. View Abstract

  120. Effect of developmental stage of HSC and recipient on transplant outcomes. Dev Cell. 2014 Jun 09; 29(5):621-628. View Abstract

  121. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell. 2014 Jul 03; 15(1):92-101. View Abstract

  122. Functional evaluation of ES-somatic cell hybrids in vitro and in vivo. Cell Reprogram. 2014 Jun; 16(3):167-74. View Abstract

  123. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev. 2014 May 01; 28(9):971-82. View Abstract

  124. Musashi-2 controls cell fate, lineage bias, and TGF-ß signaling in HSCs. J Exp Med. 2014 Jan 13; 211(1):71-87. View Abstract

  125. Defining cellular identity through network biology. Cell Cycle. 2014; 13(21):3313-4. View Abstract

  126. Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kdm4c in mouse embryonic stem cell identity. Mol Cell. 2014 01 09; 53(1):32-48. View Abstract

  127. Development. A stem cell perspective on cellular engineering. Science. 2013 Nov 08; 342(6159):700-2. View Abstract

  128. Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell. 2013 Nov 07; 155(4):778-92. View Abstract

  129. Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. Retrovirology. 2013 Oct 24; 10:115. View Abstract

  130. Proteolytic autodigestion: common tissue pathology in Shwachman-Diamond syndrome? Cell Cycle. 2013; 12(22):3457-8. View Abstract

  131. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell. 2013 Oct 03; 13(4):459-70. View Abstract

  132. Hematopoietic defects and iPSC disease modeling: lessons learned. Immunol Lett. 2013 Sep-Oct; 155(1-2):18-20. View Abstract

  133. Stem cells: Reprogramming in situ. Nature. 2013 Oct 17; 502(7471):309-10. View Abstract

  134. A chemical logic for reprogramming to pluripotency. Cell Res. 2013 Dec; 23(12):1337-8. View Abstract

  135. Fetal deficiency of lin28 programs life-long aberrations in growth and glucose metabolism. Stem Cells. 2013 Aug; 31(8):1563-73. View Abstract

  136. Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 2013 Oct; 41(19):9049-61. View Abstract

  137. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013 Jul; 31(7):1287-97. View Abstract

  138. A new route to human embryonic stem cells. Nat Med. 2013 Jul; 19(7):820-1. View Abstract

  139. Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Sci Transl Med. 2013 Jun 05; 5(188):188le2. View Abstract

  140. Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embryonic and induced pluripotent stem cells. Blood. 2013 Aug 15; 122(7):1162-73. View Abstract

  141. Stem cell metabolism in tissue development and aging. Development. 2013 Jun; 140(12):2535-47. View Abstract

  142. Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol. 2013 Jun; 14(6):357-68. View Abstract

  143. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J. 2013 May 29; 32(11):1489-95. View Abstract

  144. Lin28a regulates germ cell pool size and fertility. Stem Cells. 2013 May; 31(5):1001-9. View Abstract

  145. Deciphering the rules of ceRNA networks. Proc Natl Acad Sci U S A. 2013 Apr 30; 110(18):7112-3. View Abstract

  146. Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell. 2013 Jun 06; 12(6):727-36. View Abstract

  147. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 2013 Apr 04; 12(4):395-406. View Abstract

  148. The Src homology 2 protein Shb promotes cell cycle progression in murine hematopoietic stem cells by regulation of focal adhesion kinase activity. Exp Cell Res. 2013 Jul 15; 319(12):1852-1864. View Abstract

  149. A blueprint for engineering cell fate: current technologies to reprogram cell identity. Cell Res. 2013 Jan; 23(1):33-48. View Abstract

  150. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med. 2013; 64:277-90. View Abstract

  151. Signaling axis involving Hedgehog, Notch, and Scl promotes the embryonic endothelial-to-hematopoietic transition. Proc Natl Acad Sci U S A. 2013 Jan 08; 110(2):E141-50. View Abstract

  152. Cellular alchemy and the golden age of reprogramming. Cell. 2012 Dec 07; 151(6):1151-4. View Abstract

  153. Zcchc11 uridylates mature miRNAs to enhance neonatal IGF-1 expression, growth, and survival. PLoS Genet. 2012; 8(11):e1003105. View Abstract

  154. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell. 2012 Nov 02; 11(5):589-95. View Abstract

  155. The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell. 2012 Nov 02; 11(5):701-14. View Abstract

  156. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science. 2013 Jan 11; 339(6116):222-6. View Abstract

  157. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature. 2012 Nov 29; 491(7426):769-73. View Abstract

  158. Euchromatin islands in large heterochromatin domains are enriched for CTCF binding and differentially DNA-methylated regions. BMC Genomics. 2012 Oct 26; 13:566. View Abstract

  159. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):17567-72. View Abstract

  160. Therapeutic potential of human induced pluripotent stem cells in experimental stroke. Cell Transplant. 2013; 22(8):1427-40. View Abstract

  161. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J. 2012 Sep 15; 446(3):359-71. View Abstract

  162. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells. 2012 Sep; 30(9):2054-62. View Abstract

  163. Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. Cardiovasc Res. 2012 Dec 01; 96(3):391-400. View Abstract

  164. Caudal genes in blood development and leukemia. Ann N Y Acad Sci. 2012 Aug; 1266:47-54. View Abstract

  165. New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev. 2012 Oct; 22(5):500-8. View Abstract

  166. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012 Jun 14; 10(6):740-749. View Abstract

  167. Stem cells assessed. Nat Rev Mol Cell Biol. 2012 06 08; 13(7):471-6. View Abstract

  168. Pluripotent stem cells in research and treatment of hemoglobinopathies. Cold Spring Harb Perspect Med. 2012 Apr; 2(4):a011841. View Abstract

  169. Accessing naïve human pluripotency. Curr Opin Genet Dev. 2012 Jun; 22(3):272-82. View Abstract

  170. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5803-8. View Abstract

  171. Reprogramming cellular identity for regenerative medicine. Cell. 2012 Mar 16; 148(6):1110-22. View Abstract

  172. Nanog-like regulates endoderm formation through the Mxtx2-Nodal pathway. Dev Cell. 2012 Mar 13; 22(3):625-38. View Abstract

  173. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 04; 483(7391):598-602. View Abstract

  174. Overcoming reprogramming resistance of Fanconi anemia cells. Blood. 2012 Jun 07; 119(23):5449-57. View Abstract

  175. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012 Jan 18; 481(7381):295-305. View Abstract

  176. Derivation of human embryonic stem cells with NEMO deficiency. Stem Cell Res. 2012 May; 8(3):410-5. View Abstract

  177. Excision of a viral reprogramming cassette by delivery of synthetic Cre mRNA. Curr Protoc Stem Cell Biol. 2012; Chapter 4:Unit4A.5. View Abstract

  178. Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res. 2012 Feb 03; 110(3):406-15. View Abstract

  179. Live-cell immunofluorescence staining of human pluripotent stem cells. Curr Protoc Stem Cell Biol. 2011 Dec; Chapter 1:Unit 1C.12. View Abstract

  180. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol. 2011 Nov 27; 29(12):1117-9. View Abstract

  181. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011 Nov 27; 29(12):1132-44. View Abstract

  182. Cell cycle adaptations of embryonic stem cells. Proc Natl Acad Sci U S A. 2011 Nov 29; 108(48):19252-7. View Abstract

  183. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011 Nov 11; 10(12):915-29. View Abstract

  184. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell. 2011 Oct 28; 147(3):577-89. View Abstract

  185. Stem cells: Triple genomes go far. Nature. 2011 Oct 05; 478(7367):40-1. View Abstract

  186. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011 Sep 30; 147(1):81-94. View Abstract

  187. Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol. 2011 Sep 11; 13(10):1214-23. View Abstract

  188. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell. 2011 Aug 19; 146(4):607-20. View Abstract

  189. Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci. 2011 Aug 12; 366(1575):2274-85. View Abstract

  190. Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Res. 2011 Aug; 21(8):1157-60. View Abstract

  191. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann Neurol. 2011 Sep; 70(3):402-9. View Abstract

  192. microRNAs become macro players in somatic cell reprogramming. Genome Med. 2011 Jun 22; 3(6):40. View Abstract

  193. The nomenclature system should be sustainable, but also practical. Cell Stem Cell. 2011 Jun 03; 8(6):606-7. View Abstract

  194. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011 May 19; 473(7347):394-7. View Abstract

  195. Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One. 2011 Apr 29; 6(4):e18992. View Abstract

  196. Induced pluripotent stem cells for neural tissue engineering. Biomaterials. 2011 Aug; 32(22):5023-32. View Abstract

  197. Interactions between Cdx genes and retinoic acid modulate early cardiogenesis. Dev Biol. 2011 Jun 01; 354(1):134-42. View Abstract

  198. Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet. 2011 Apr; 12(4):266-75. View Abstract

  199. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011 Mar 03; 471(7336):63-7. View Abstract

  200. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011 Feb 04; 8(2):200-13. View Abstract

  201. Stage-specific signaling through TGFß family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development. 2011 Mar; 138(5):861-71. View Abstract

  202. Cellular therapy for fanconi anemia: the past, present, and future. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S109-14. View Abstract

  203. Genomic approaches to deconstruct pluripotency. Annu Rev Genomics Hum Genet. 2011; 12:165-85. View Abstract

  204. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011 Jun; 127(6):1400-7.e4. View Abstract

  205. Another horse in the meta-stable state of pluripotency. Cell Stem Cell. 2010 Dec 03; 7(6):641-2. View Abstract

  206. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell. 2010 Dec 03; 7(6):671-81. View Abstract

  207. From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond. Genes Cancer. 2010 Dec; 1(12):1164-9. View Abstract

  208. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010 Dec; 42(12):1113-7. View Abstract

  209. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. 2011 Jan 20; 117(3):839-47. View Abstract

  210. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010 Nov 05; 7(5):618-30. View Abstract

  211. Dynamic instability of genomic methylation patterns in pluripotent stem cells. Epigenetics Chromatin. 2010 Sep 24; 3(1):17. View Abstract

  212. Epigenetic memory in induced pluripotent stem cells. Nature. 2010 Sep 16; 467(7313):285-90. View Abstract

  213. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature. 2010 Sep 16; 467(7313):338-42. View Abstract

  214. Clump passaging and expansion of human embryonic and induced pluripotent stem cells on mouse embryonic fibroblast feeder cells. Curr Protoc Stem Cell Biol. 2010 Aug; Chapter 1:Unit 1C.10. View Abstract

  215. All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One. 2010 Jul 13; 5(7):e11513. View Abstract

  216. Molecular basis of the first cell fate determination in mouse embryogenesis. Cell Res. 2010 Sep; 20(9):982-93. View Abstract

  217. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010 Aug; 16(8):903-8. View Abstract

  218. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010 Jul 02; 7(1):15-9. View Abstract

  219. Straight talk with...George Daley. Interview by Elie Dolgin. Nat Med. 2010 Jun; 16(6):624. View Abstract

  220. Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev Rep. 2010 Jun; 6(2):270-81. View Abstract

  221. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet. 2010 Jul; 42(7):626-30. View Abstract

  222. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica. 2010 Oct; 95(10):1642-50. View Abstract

  223. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010 May 07; 6(5):407-11. View Abstract

  224. Interaction of retinoic acid and scl controls primitive blood development. Blood. 2010 Jul 15; 116(2):201-9. View Abstract

  225. AID for reprogramming. Cell Res. 2010 Mar; 20(3):253-5. View Abstract

  226. Lin28: A microRNA regulator with a macro role. Cell. 2010 Feb 19; 140(4):445-9. View Abstract

  227. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature. 2010 Mar 11; 464(7286):292-6. View Abstract

  228. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood. 2010 Apr 29; 115(17):3453-62. View Abstract

  229. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28; 463(7280):501-6. View Abstract

  230. Stem cells: roadmap to the clinic. J Clin Invest. 2010 Jan; 120(1):8-10. View Abstract

  231. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology. 2010 Jan; 51(1):329-35. View Abstract

  232. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des. 2010 Feb; 75(2):223-7. View Abstract

  233. A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet. 2009 Nov; 5(11):e1000718. View Abstract

  234. Autologous blood cell therapies from pluripotent stem cells. Blood Rev. 2010 Jan; 24(1):27-37. View Abstract

  235. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009 Dec; 41(12):1350-3. View Abstract

  236. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol. 2009 Nov; 27(11):1033-7. View Abstract

  237. Disease models from pluripotent stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:191-6. View Abstract

  238. Hematopoietic development from human induced pluripotent stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:219-27. View Abstract

  239. 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13; 52(15):4743-56. View Abstract

  240. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature. 2009 Aug 13; 460(7257):909-13. View Abstract

  241. microRNA expression during trophectoderm specification. PLoS One. 2009 Jul 03; 4(7):e6143. View Abstract

  242. Balancing work and life: a conversation with George Daley. Interviewed by Majlinda Lako and Susan Daher. Stem Cells. 2009 Jul; 27(7):1469-70. View Abstract

  243. Cross-regulation of the Nanog and Cdx2 promoters. Cell Res. 2009 Sep; 19(9):1052-61. View Abstract

  244. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. 2009 Jul 02; 5(1):97-110. View Abstract

  245. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009 Jul 09; 460(7252):259-63. View Abstract

  246. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8. View Abstract

  247. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009 Jun 25; 459(7250):1126-30. View Abstract

  248. Biomechanical forces promote embryonic haematopoiesis. Nature. 2009 Jun 25; 459(7250):1131-5. View Abstract

  249. Surface antigen phenotypes of hematopoietic stem cells from embryos and murine embryonic stem cells. Blood. 2009 Jul 09; 114(2):268-78. View Abstract

  250. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009 May; 27(5):993-1005. View Abstract

  251. Upping the ante: recent advances in direct reprogramming. Mol Ther. 2009 Jun; 17(6):947-53. View Abstract

  252. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009 Apr; 27(4):361-8. View Abstract

  253. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol. 2009 Apr; 27(4):353-60. View Abstract

  254. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009 Mar 20; 136(6):1136-47. View Abstract

  255. Generation of induced pluripotent stem cells from human blood. Blood. 2009 May 28; 113(22):5476-9. View Abstract

  256. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell. 2009 Mar 06; 4(3):200-1; author reply 202. View Abstract

  257. ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood. 2009 Apr 16; 113(16):3813-20. View Abstract

  258. Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb Symp Quant Biol. 2008; 73:171-4. View Abstract

  259. Human iPS cell derivation/reprogramming. Curr Protoc Stem Cell Biol. 2009 Jan; Chapter 4:Unit 4A.1. View Abstract

  260. Efficient gene knockdowns in human embryonic stem cells using lentiviral-based RNAi. Methods Mol Biol. 2009; 482:35-42. View Abstract

  261. Application of induced pluripotent stem cells to hematologic disease. Cytotherapy. 2009; 11(8):980-9. View Abstract

  262. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell. 2008 Dec 04; 3(6):607-9. View Abstract

  263. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008 Nov; 22(11):1975-89. View Abstract

  264. From fibroblasts to iPS cells: induced pluripotency by defined factors. J Cell Biochem. 2008 Nov 01; 105(4):949-55. View Abstract

  265. Mesodermal patterning activity of SCL. Exp Hematol. 2008 Dec; 36(12):1593-603. View Abstract

  266. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008 Oct; 15(10):1109-18. View Abstract

  267. Disease-specific induced pluripotent stem cells. Cell. 2008 Sep 05; 134(5):877-86. View Abstract

  268. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem. 2008 Aug 01; 283(31):21310-4. View Abstract

  269. Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos. Nat Genet. 2008 Jul; 40(7):921-6. View Abstract

  270. Cdx gene deficiency compromises embryonic hematopoiesis in the mouse. Proc Natl Acad Sci U S A. 2008 Jun 03; 105(22):7756-61. View Abstract

  271. Molecular basis of pluripotency. Hum Mol Genet. 2008 Apr 15; 17(R1):R23-7. View Abstract

  272. Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J Clin Invest. 2008 Apr; 118(4):1511-8. View Abstract

  273. Enhanced plating efficiency of trypsin-adapted human embryonic stem cells is reversible and independent of trisomy 12/17. Cloning Stem Cells. 2008 Mar; 10(1):107-18. View Abstract

  274. Prospects for stem cell-based therapy. Cell. 2008 Feb 22; 132(4):544-8. View Abstract

  275. Selective blockade of microRNA processing by Lin28. Science. 2008 Apr 04; 320(5872):97-100. View Abstract

  276. Modulation of murine embryonic stem cell-derived CD41+c-kit+ hematopoietic progenitors by ectopic expression of Cdx genes. Blood. 2008 May 15; 111(10):4944-53. View Abstract

  277. Isolation of hematopoietic stem cells from mouse embryonic stem cells. Curr Protoc Stem Cell Biol. 2008 Feb; Chapter 1:Unit 1F.3. View Abstract

  278. Human embryonic stem cell derivation from poor-quality embryos. Nat Biotechnol. 2008 Feb; 26(2):212-4. View Abstract

  279. BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell. 2008 Jan 10; 2(1):72-82. View Abstract

  280. Derivation and maintenance of human embryonic stem cells from poor-quality in vitro fertilization embryos. Nat Protoc. 2008; 3(5):923-33. View Abstract

  281. Generation of human-induced pluripotent stem cells. Nat Protoc. 2008; 3(7):1180-6. View Abstract

  282. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008 Jan 10; 451(7175):141-6. View Abstract

  283. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302. View Abstract

  284. Current prospects for the generation of patient-specific pluripotent cells from adult tissues. Regen Med. 2007 Sep; 2(5):743-52. View Abstract

  285. Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. Cell Stem Cell. 2007 Sep 13; 1(3):253-8. View Abstract

  286. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82. View Abstract

  287. Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and somatic cell nuclear transfer. Cell Stem Cell. 2007 Sep 13; 1(3):346-52. View Abstract

  288. Debugging cellular reprogramming. Nat Cell Biol. 2007 Aug; 9(8):871-3. View Abstract

  289. Hemogenic endothelial progenitor cells isolated from human umbilical cord blood. Stem Cells. 2007 Nov; 25(11):2770-6. View Abstract

  290. Towards hematopoietic reconstitution from embryonic stem cells: a sanguine future. Curr Opin Hematol. 2007 Jul; 14(4):343-7. View Abstract

  291. Human embryonic stem cells flock together. Nat Biotechnol. 2007 Jul; 25(7):748-50. View Abstract

  292. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007 Jun 21; 447(7147):1007-11. View Abstract

  293. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9. View Abstract

  294. Gametes from embryonic stem cells: a cup half empty or half full? Science. 2007 Apr 20; 316(5823):409-10. View Abstract

  295. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood. 2007 Jul 01; 110(1):171-9. View Abstract

  296. Differentiation potential of histocompatible parthenogenetic embryonic stem cells. Ann N Y Acad Sci. 2007 Jun; 1106:209-18. View Abstract

  297. Derivation of hematopoietic stem cells from murine embryonic stem cells. J Vis Exp. 2007 Feb 25; (2):162. View Abstract

  298. The cdx-hox pathway in hematopoietic stem cell formation from embryonic stem cells. Ann N Y Acad Sci. 2007 Jun; 1106:197-208. View Abstract

  299. Ethics. The ISSCR guidelines for human embryonic stem cell research. Science. 2007 Feb 02; 315(5812):603-4. View Abstract

  300. Towards the generation of patient-specific pluripotent stem cells for combined gene and cell therapy of hematologic disorders. Hematology Am Soc Hematol Educ Program. 2007; 17-22. View Abstract

  301. Histocompatible embryonic stem cells by parthenogenesis. Science. 2007 Jan 26; 315(5811):482-6. View Abstract

  302. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proc Natl Acad Sci U S A. 2006 Nov 07; 103(45):16924-9. View Abstract

  303. Progress and prospects: gene transfer into embryonic stem cells. Gene Ther. 2006 Oct; 13(20):1431-9. View Abstract

  304. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9244-9. View Abstract

  305. Stem cells and their niche: a matter of fate. Cell Mol Life Sci. 2006 Apr; 63(7-8):760-6. View Abstract

  306. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52. View Abstract

  307. Acceleration of mesoderm development and expansion of hematopoietic progenitors in differentiating ES cells by the mouse Mix-like homeodomain transcription factor. Blood. 2006 Apr 15; 107(8):3122-30. View Abstract

  308. Male germ cells. Methods Enzymol. 2006; 418:307-14. View Abstract

  309. Transgene expression and RNA interference in embryonic stem cells. Methods Enzymol. 2006; 420:49-64. View Abstract

  310. Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. Mol Diagn Ther. 2006; 10(2):67-76. View Abstract

  311. In vitro generation of germ cells from murine embryonic stem cells. Nat Protoc. 2006; 1(4):2026-36. View Abstract

  312. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res. 2005 Dec 15; 65(24):11572-80. View Abstract

  313. Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):19081-6. View Abstract

  314. Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells. Blood. 2006 Apr 01; 107(7):2605-12. View Abstract

  315. Therapeutic potential of embryonic stem cells. Blood Rev. 2005 Nov; 19(6):321-31. View Abstract

  316. Patterning definitive hematopoietic stem cells from embryonic stem cells. Exp Hematol. 2005 Sep; 33(9):971-9. View Abstract

  317. Customized human embryonic stem cells. Nat Biotechnol. 2005 Jul; 23(7):826-8. View Abstract

  318. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene. 2005 May 05; 24(20):3257-67. View Abstract

  319. High-efficiency RNA interference in human embryonic stem cells. Stem Cells. 2005 Mar; 23(3):299-305. View Abstract

  320. The homeobox gene HEX regulates proliferation and differentiation of hemangioblasts and endothelial cells during ES cell differentiation. Blood. 2005 Jun 15; 105(12):4590-7. View Abstract

  321. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb; 7(2):129-41. View Abstract

  322. Stem cell research: science, ethics and policy. Med Ethics (Burlingt Mass). 2005; 12(1):5. View Abstract

  323. Inducible transgene expression in mouse stem cells. Methods Mol Med. 2005; 105:23-46. View Abstract

  324. Altered nuclear transfer in stem-cell research - a flawed proposal. N Engl J Med. 2004 Dec 30; 351(27):2791-2. View Abstract

  325. In vitro gametogenesis from embryonic stem cells. Curr Opin Cell Biol. 2004 Dec; 16(6):688-92. View Abstract

  326. Chronic myeloid leukemia: proving ground for cancer stem cells. Cell. 2004 Oct 29; 119(3):314-6. View Abstract

  327. Bayesian analysis of signaling networks governing embryonic stem cell fate decisions. Bioinformatics. 2005 Mar; 21(6):741-53. View Abstract

  328. Missed opportunities in embryonic stem-cell research. N Engl J Med. 2004 Aug 12; 351(7):627-8. View Abstract

  329. Alchemy in the liver: fact or fusion? Nat Med. 2004 Jul; 10(7):671-2. View Abstract

  330. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene. 2004 Jun 03; 23(26):4641-5. View Abstract

  331. Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J Neurosci Res. 2004 Apr 15; 76(2):157-68. View Abstract

  332. Multivariate proteomic analysis of murine embryonic stem cell self-renewal versus differentiation signaling. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2900-5. View Abstract

  333. Genetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation. Oncogene. 2004 Feb 12; 23(6):1214-20. View Abstract

  334. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004 Jan; 11(1):35-43. View Abstract

  335. Origins of mammalian hematopoiesis: in vivo paradigms and in vitro models. Curr Top Dev Biol. 2004; 60:127-96. View Abstract

  336. Nuclear transplantation, embryonic stem cells and the potential for cell therapy. Hematol J. 2004; 5 Suppl 3:S114-7. View Abstract

  337. LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells. 2004; 22(5):770-8. View Abstract

  338. Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature. 2004 Jan 08; 427(6970):148-54. View Abstract

  339. Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. Leukemia. 2003 Dec; 17(12):2358-82. View Abstract

  340. Hematopoiesis from embryonic stem cells: lessons from and for ontogeny. Exp Hematol. 2003 Nov; 31(11):994-1006. View Abstract

  341. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003; 5:204-210. View Abstract

  342. cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature. 2003 Sep 18; 425(6955):300-6. View Abstract

  343. Enhanced hematopoietic differentiation of embryonic stem cells conditionally expressing Stat5. Proc Natl Acad Sci U S A. 2003 Sep 30; 100 Suppl 1:11904-10. View Abstract

  344. Cloning and stem cells--handicapping the political and scientific debates. N Engl J Med. 2003 Jul 17; 349(3):211-2. View Abstract

  345. ES cells prove egg-straordinary. Nat Biotechnol. 2003 Jul; 21(7):760-1. View Abstract

  346. Gleevec resistance: lessons for target-directed drug development. Cell Cycle. 2003 May-Jun; 2(3):190-1. View Abstract

  347. From embryos to embryoid bodies: generating blood from embryonic stem cells. Ann N Y Acad Sci. 2003 May; 996:122-31. View Abstract

  348. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol. 2003 Apr; 40(2 Suppl 2):11-4. View Abstract

  349. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003 Mar 21; 112(6):831-43. View Abstract

  350. Dodging the magic bullet: understanding imatinib resistance. Cancer Biol Ther. 2003 Jan-Feb; 2(1):109-10. View Abstract

  351. A role for thrombopoietin in hemangioblast development. Stem Cells. 2003; 21(3):272-80. View Abstract

  352. Realistic prospects for stem cell therapeutics. Hematology Am Soc Hematol Educ Program. 2003; 398-418. View Abstract

  353. Development of hematopoietic repopulating cells from embryonic stem cells. Methods Enzymol. 2003; 365:114-29. View Abstract

  354. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 2002 Dec 15; 30(24):e142. View Abstract

  355. Prospects for stem cell therapeutics: myths and medicines. Curr Opin Genet Dev. 2002 Oct; 12(5):607-13. View Abstract

  356. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002 Aug 01; 100(3):1068-71. View Abstract

  357. Efficiency of embryoid body formation and hematopoietic development from embryonic stem cells in different culture systems. Biotechnol Bioeng. 2002 May 20; 78(4):442-53. View Abstract

  358. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002 Apr 05; 109(1):17-27. View Abstract

  359. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell. 2002 Apr 05; 109(1):29-37. View Abstract

  360. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev. 2002 Mar 15; 16(6):681-6. View Abstract

  361. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol. 2002 Feb; 4(2):148-53. View Abstract

  362. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res. 2002 Jan 15; 62(2):535-41. View Abstract